What is the role of sphingolipids in asthma and obesity associated asthma?
Sphingolipids play a multifaceted role in the pathogenesis of asthma and obesity-associated asthma, acting as critical signaling molecules that influence inflammation, immune cell activation, and airway hyperresponsiveness. In asthma, variations in sphingolipid concentrations, particularly ceramide and sphingosine-1-phosphate (S1P), have been strongly associated with the disease, influencing immune cell activation and allergic inflammation. Obesity further alters lipid metabolites, including sphingolipids, contributing to inflammation that may exacerbate asthma in obese individuals. Specifically, obese asthma patients exhibit higher levels of certain ceramides, indicating a metabolic shift favoring ceramide accumulation, which is linked to increased airway hyperresponsiveness and M1 macrophage polarization. Sphingomyelin (SM) levels, a type of sphingolipid, are significantly decreased in asthmatic patients compared to healthy controls, suggesting a protective role of SM against asthma. Environmental factors, such as exposure to pollutants, have been shown to affect sphingolipid levels, including S1P and ceramide-1-phosphate (C1P), potentially defining a novel asthma endotype influenced by environmental exposures. Genetic factors also play a role, with certain genetic loci associated with asthma influencing the expression of ORMDL3, a regulator of sphingolipid synthesis, thereby affecting sphingolipid levels and asthma susceptibility. In the context of obesity, elevated serum triglycerides, another lipid class, have been associated with asthma, suggesting a link between lipid metabolism and asthma in obese patients. Sphingolipid metabolism's disruption is strongly associated with diseases exhibiting metabolic consequences, including obesity. Furthermore, sphingolipid metabolites like S1P are involved in mast cell differentiation, proliferation, and inflammatory responses, highlighting their role in allergic diseases and asthma pathogenesis. In summary, sphingolipids contribute to asthma and obesity-associated asthma through their roles in inflammation, immune cell regulation, and response to environmental and genetic factors, offering potential targets for therapeutic intervention.
Answers from top 10 papers
Papers (10) | Insight |
---|---|
26 Citations | Sphingosine-1-phosphate (S1P) plays a crucial role in mast cell functions in asthma. However, the paper does not address the specific role of sphingolipids in obesity-associated asthma. |
32 Citations | Not addressed in the paper. |
4 Citations | Not addressed in the paper. |
21 Citations | Sphingolipids play a crucial role in asthma by influencing mast cell biology. The paper does not address the specific role of sphingolipids in obesity-associated asthma. |
4 Citations | Sphingolipids play a dual role in asthma, influencing airway hyperresponsiveness. While altered levels contribute to asthma pathophysiology, their manipulation shows promise in opposing airway hyperresponsiveness. |
14 Jun 2021 8 Citations | Sphingolipids play a crucial role in asthma by regulating inflammation and barrier integrity. While not directly addressed in the paper, their involvement in obesity-associated asthma warrants further investigation. |
1 Citations | Sphingolipids play a crucial role in asthma by influencing airway features. The paper does not address the specific link between sphingolipids and obesity-associated asthma. |
Sphingolipids, particularly S1P and C1P, are elevated in asthma, potentially influenced by environmental pollutants. Their role in obesity-associated asthma is not addressed in the paper. | |
7 Citations | Sphingolipids, particularly sphingomyelin (SM), are decreased in asthma patients. SM levels are lower in noneosinophilic asthma and may serve as a biomarker and therapeutic target in asthma. |
14 Citations | Sphingolipids, particularly C18:0 ceramide, accumulate in obese asthma, potentially contributing to its development by favoring ceramide accumulation and metabolic shifts, leading to inflammation and airway hyperresponsiveness. |